(Q37990403)

26 August 2017

title

¹¹¹In-DTPA⁰-octreotide (Octreoscan), ¹³¹I-MIBG and other agents for radionuclide therapy of NETs (English)

1 reference

26 August 2017

Jamshed B Bomanji

1

1 reference

26 August 2017

Nikolaos D Papathanasiou

series ordinal

2

1 reference

26 August 2017

publication date

1 February 2012

1 reference

European Journal of Nuclear Medicine and Molecular Imaging

26 August 2017

published in

1 reference

26 August 2017

volume

39 Suppl 1

1 reference

26 August 2017

page(s)

S113-25

1 reference

Gastroenteropancreatic neuroendocrine tumours

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2013-8

One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2013-8

Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2013-8

Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2013-8

Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2013-8

Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2013-8

Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2013-8

Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2013-8

Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2013-8

Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2013-8

Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2013-8

Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2013-8

Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2013-8

Safety and efficacy of radionuclide therapy with high-activity In-111 pentetreotide in patients with progressive neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2013-8

Selective hepatic arterial infusion of In-111-DTPA-Phe1-octreotide in neuroendocrine liver metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2013-8

111In-labelled somatostatin analogues in a rat tumour model: somatostatin receptor status and effects of peptide receptor radionuclide therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2013-8

Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2013-8

Radioiodinated metaiodobenzylguanidine: a review of its biodistribution and pharmacokinetics, drug interactions, cytotoxicity and dosimetry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2013-8

Intracellular localization of metaiodobenzyl guanidine in human neuroblastoma cells by electron spectroscopic imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2013-8

Scintigraphic Localization of Pheochromocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2013-8

Current role of metaiodobenzylguanidine in the diagnosis of pheochromocytoma and medullary thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2013-8

EANM procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2013-8

Long-term efficacy of low activity meta-[131I]iodobenzylguanidine therapy in patients with disseminated neuroendocrine tumours depends on initial response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2013-8

Low-dose iodine-131 metaiodobenzylguanidine therapy for patients with malignant pheochromocytoma and paraganglioma: single center experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2013-8

Treatment of neuroendocrine tumours in adults with 131I-MIBG therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2013-8

Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2013-8

Efficacy of using a standard activity of (131)I-MIBG therapy in patients with disseminated neuroendocrine tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2013-8

Malignant pheochromocytoma: state of the field with future projections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2013-8

Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2013-8

Clinical use and utility of metaiodobenzylguanidine scintigraphy in pheochromocytoma diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2013-8

Usefulness of 123I-MIBG scintigraphy in the evaluation of patients with known or suspected primary or metastatic pheochromocytoma or paraganglioma: results from a prospective multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2013-8

The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2013-8

Iodine -131 metaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2013-8

Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2013-8

Patient dosimetry for 131I-MIBG therapy for neuroendocrine tumours based on 123I-MIBG scans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2013-8

Functional imaging in phaeochromocytoma and neuroblastoma with 68Ga-DOTA-Tyr 3-octreotide positron emission tomography and 123I-metaiodobenzylguanidine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2013-8

Assessment of the efficacy and toxicity of (131)I-metaiodobenzylguanidine therapy for metastatic neuroendocrine tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2013-8

Iodine-131 metaiodobenzylguanidine treatment for metastatic carcinoid. Results in 98 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2013-8

Imaging of neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2013-8

Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2013-8

Comparison of (68)Ga-DOTATATE and (18)F-fluorodeoxyglucose PET/CT in the detection of recurrent medullary thyroid carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2013-8

131I-metaiodobenzylguanidine therapy of neuroblastoma and other neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2013-8

Radioiodinated metaiodobenzylguanidine (MIBG): radiochemistry, biology, and pharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2013-8

Comparison of high-specific-activity ultratrace 123/131I-MIBG and carrier-added 123/131I-MIBG on efficacy, pharmacokinetics, and tissue distribution

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2013-8

Preclinical assessment of strategies for enhancement of metaiodobenzylguanidine therapy of neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2013-8

Feasibility of dosimetry-based high-dose 131I-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2013-8

Treatment of malignant pheochromocytomas with 131-I metaiodobenzylguanidine and chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2013-8

Increased uptake of [¹²³I]meta-iodobenzylguanidine, [¹⁸F]fluorodopamine, and [³H]norepinephrine in mouse pheochromocytoma cells and tumors after treatment with the histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2013-8

Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2013-8

Glucagon-like peptide-1 receptor imaging for localization of insulinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2013-8

[Lys40(Ahx-DTPA-111In)NH2]-Exendin-4 is a highly efficient radiotherapeutic for glucagon-like peptide-1 receptor-targeted therapy for insulinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2013-8

Evaluation of CCK2 receptor binding ligands: the inheritance of Thomas Behr

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2013-8

Comparison of the binding and internalization properties of 12 DOTA-coupled and ¹¹¹In-labelled CCK2/gastrin receptor binding peptides: a collaborative project under COST Action BM0607.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2013-8

Comparative biodistribution of 12 ¹¹¹In-labelled gastrin/CCK2 receptor-targeting peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2013-8

131I-MIBG therapy in metastatic phaeochromocytoma and paraganglioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2013-8

Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with (131)I-meta-iodobenzylguanidine [(131)I-mIBG].

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2013-8

10.1007/S00259-011-2013-8

21 January 2018

Identifiers

DOI

1 reference

26 August 2017

1 reference